These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 3502110)

  • 1. v-H-ras gene reduces IL-3 requirement in PB-3c mastocytes in vitro followed by autokrine tumor formation in vivo.
    Nair AP; Moroni C
    Haematol Blood Transfus; 1987; 31():257-60. PubMed ID: 3502110
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor-promoting phorbol ester and activated Ha-ras synergistically reduce the interleukin 3 requirement in a mast cell line.
    Imber R; Fabbro D
    Cancer Res; 1991 Jan; 51(2):632-8. PubMed ID: 1985780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mast cells sensitive to v-H-ras transformation are hyperinducible for interleukin 3 expression and have lost tumor-suppressor activity.
    Nair AP; Hirsch HH; Moroni C
    Oncogene; 1992 Oct; 7(10):1963-72. PubMed ID: 1408138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V-Ha-ras-dependent expression of interleukin-3 mRNA in premalignant PB-3c mast cells correlates with the formation of tumors without interleukin-3 gene rearrangements.
    Aebersold DM; Banholzer R; Backenstoss V; Hirsch HH; Moroni C
    Exp Hematol; 1997 May; 25(5):395-404. PubMed ID: 9168061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppressible and nonsuppressible autocrine mast cell tumors are distinguished by insertion of an endogenous retroviral element (IAP) into the interleukin 3 gene.
    Hirsch HH; Nair AP; Moroni C
    J Exp Med; 1993 Aug; 178(2):403-11. PubMed ID: 8340751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A v-H-ras-dependent hemopoietic tumor model involving progression from a clonal stage of transformation competence to autocrine interleukin 3 production.
    Nair AP; Diamantis ID; Conscience JF; Kindler V; Hofer P; Moroni C
    Mol Cell Biol; 1989 Mar; 9(3):1183-90. PubMed ID: 2498644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA.
    Stoecklin G; Gross B; Ming XF; Moroni C
    Oncogene; 2003 Jun; 22(23):3554-61. PubMed ID: 12789264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of cytokine expression in PB-3c mastocytes by IBMX and PMA.
    Hahn S; Moroni C
    Lymphokine Cytokine Res; 1994 Aug; 13(4):247-52. PubMed ID: 7528062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive c-myc expression enhances the response of murine mast cells to IL-3, but does not eliminate their requirement for growth factors.
    Hume CR; Nocka KH; Sorrentino V; Lee JS; Fleissner E
    Oncogene; 1988 Mar; 2(3):223-6. PubMed ID: 3281092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor suppression involves down-regulation of interleukin 3 expression in hybrids between autocrine mastocytoma and interleukin 3-dependent parental mast cells.
    Diamantis ID; Nair AP; Hirsch HH; Moroni C
    Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9299-302. PubMed ID: 2512578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells.
    Drube S; Weber F; Loschinski R; Beyer M; Rothe M; Rabenhorst A; Göpfert C; Meininger I; Diamanti MA; Stegner D; Häfner N; Böttcher M; Reinecke K; Herdegen T; Greten FR; Nieswandt B; Hartmann K; Krämer OH; Kamradt T
    Oncotarget; 2015 Mar; 6(7):5354-68. PubMed ID: 25749030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganglioside GM3 inhibits interleukin-3-dependent bone marrow-derived mast cell proliferation.
    Fujimaki H; Nohara O; Katayama N; Abe T; Nohara K
    Int Arch Allergy Immunol; 1995 Aug; 107(4):527-32. PubMed ID: 7620368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Pim-1 function in mutant mice.
    Domen J; van der Lugt NM; Laird PW; Saris CJ; Berns A
    Leukemia; 1993 Aug; 7 Suppl 2():S108-12. PubMed ID: 8361211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered protein kinase C in a mast cell variant defective in exocytosis.
    Mazurek N; Regazzi R; Borner C; Wyss R; Conscience JF; Erne P; Eppenberger U; Fabbro D
    Proc Natl Acad Sci U S A; 1987 Mar; 84(5):1277-81. PubMed ID: 3493490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporin A inhibits growth of autocrine tumour cell lines by destabilizing interleukin-3 mRNA.
    Nair AP; Hahn S; Banholzer R; Hirsch HH; Moroni C
    Nature; 1994 May; 369(6477):239-42. PubMed ID: 8183344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-3-mediated TNF production is necessary for mast cell development.
    Wright HV; Bailey D; Kashyap M; Kepley CL; Drutskaya MS; Nedospasov SA; Ryan JJ
    J Immunol; 2006 Feb; 176(4):2114-21. PubMed ID: 16455967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cultured human intestinal mast cells express functional IL-3 receptors and respond to IL-3 by enhancing growth and IgE receptor-dependent mediator release.
    Gebhardt T; Sellge G; Lorentz A; Raab R; Manns MP; Bischoff SC
    Eur J Immunol; 2002 Aug; 32(8):2308-16. PubMed ID: 12209644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incapability of interleukin-4 to induce AP-1 activity in murine mast cells.
    Chaikin E; Hakeem I; Razin E
    Int Arch Allergy Immunol; 1995; 107(1-3):57-9. PubMed ID: 7613219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vanadate can replace interleukin 3 for transient growth of factor-dependent cells.
    Tojo A; Kasuga M; Urabe A; Takaku F
    Exp Cell Res; 1987 Jul; 171(1):16-23. PubMed ID: 2442014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-3 or immunoglobulin E promotes expression of protein kinase C delta gene in murine mast cells.
    Kim HM; Ko SG; Kim JJ; Chung YT; An NH
    Pharmacol Res; 1999 Aug; 40(2):147-51. PubMed ID: 10433873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.